Zepbound leads to more weight loss than Wegovy, new study finds
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
Dear S.R.: Tirzepatide (Zepbound), like semaglutide, is a prescription medication originally used for diabetes but now ...
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
1dOpinion
Biden’s Center for Medicare and Medicaid Services extends coverage by making nonsense of the law.
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback